Can University Researchers Get NIH SBIR/STTR Funding? A Guide for Drug and Medical Device Innovators

University researchers can participate in NIH SBIR/STTR-funded projects, but an eligible U.S. small business—not the university—must apply for and receive the award. The university can participate as a research partner or subcontractor, as explained in NIH’s small-business eligibility requirements.

For a team developing a medical device or drug candidate, that changes the starting question. Instead of asking only, “Can this research receive funding?” ask, “Which company would apply, what product would it develop, and what would the proposed project help it prove?”

This guide focuses on NIH small-business funding for academic spinouts and university–industry partnerships. It is not a guide to university-led research grants such as R01 awards.

From academic research to a product

A promising discovery and a commercial product are not the same thing.

A laboratory may have identified a therapeutic mechanism. The potential product could be a defined drug candidate for a specific patient population. An engineering team may have developed a new sensor. The product could be a medical device that helps clinicians make a particular decision.

NIH SBIR/STTR programs provide non-dilutive funding for small-business research and development: funding that does not require giving up equity in the business. The objective is to advance technologies with commercialization potential, not simply to extend an academic research program.

Before drafting an application, write down:

·        The drug, medical device, or other product being developed.

·        The patient, clinician, or customer it would serve.

·        The unmet medical need and current alternatives.

·        The strongest evidence supporting the approach.

·        The technical uncertainty the proposed research would resolve.

·        The development decision a successful result would make possible.

Treat these as planning questions, not a substitute for the requirements and review criteria in the funding opportunity.

Which business would apply?

A university affiliation or faculty appointment does not establish SBIR/STTR eligibility. The applicant company must meet NIH’s requirements for business structure, U.S. location, ownership and control, size, and other conditions.

The applicant could be a university spinout or an existing eligible company collaborating with the laboratory. Either way, identify the organization that would receive the award and be responsible for the project before investing heavily in proposal preparation.

If no company exists yet, incorporation is only one part of the planning process. Consider who would lead the business, what rights it would need to the technology, and how it would work with the university.

Blue Haven’s support for academic innovators focuses on connecting university research with the scientific and commercial strategy behind an SBIR/STTR application.

SBIR or STTR?

Academic involvement does not automatically make STTR the right choice. SBIR permits research partnerships; STTR requires a qualifying nonprofit research-institution partner.

The choice should reflect who can lead the project, where the work will happen, and how responsibilities will be divided—not just where the technology originated.

Planning question

NIH SBIR

NIH STTR

Who receives the award?

An eligible U.S. small business

An eligible U.S. small business

Is a research-institution partner required?

No; partnerships are permitted

Yes

Where must the principal investigator primarily work?

Generally at the small business, at award and during the project

At either the small business or the partnering research institution, subject to NIH requirements

What needs early attention?

Company research responsibilities, subcontracting limits, and PI employment

Required company/institution work shares, PI arrangements, and the collaboration structure

These are planning-level distinctions, not a complete eligibility determination. Review the detailed NIH SBIR/STTR eligibility and research-performance rules alongside the specific funding opportunity.

A faculty member who plans to remain primarily employed by the university may want to evaluate STTR closely. A company positioned to lead and perform most of the research may want to assess SBIR. Neither route should be selected without checking the actual team and work plan.

Medical device funding: define the test

For a medical device project, “improve the prototype” is a starting idea—not a fully defined research objective.

An illustrative project might ask whether a prototype can meet a specific performance threshold under conditions relevant to its intended use. The proposal concept becomes clearer when it identifies the test, benchmark, and decision that follows.

Useful planning questions include:

·        What performance gap remains between the current prototype and its intended use?

·        Which testing conditions would make the result meaningful?

·        What benchmark or comparator would establish progress?

·        How would success change the next development step?

Blue Haven’s medical device grant-writing services help innovators connect technical development with clinical value, commercialization, and a focused funding strategy.

Drug development funding: identify uncertainty

For a therapeutic project, “generate more preclinical data” leaves an important question unanswered: which data would change the development decision?

Depending on the candidate, the next uncertainty might involve exposure, selectivity, delivery, early safety, or lead-candidate selection. The task is to identify what the proposed work needs to establish and why that result matters for the product’s next step.

These are illustrative planning examples, not a universal study plan. The appropriate experiments depend on the technology, evidence, and funding opportunity.

Blue Haven’s drug development grant-writing support addresses project evaluation, scientific strategy, proposal preparation, and commercialization planning.

Connect evidence to milestones

Whether the project involves a device or therapeutic, try this exercise before outlining the application:

“If this project succeeds, the company will be able to decide whether to ______.”

Then work backward. What evidence would support that decision? Which experiments would produce it? What result would indicate that the approach needs to change?

This helps separate a product-development milestone from a list of research activities. For related guidance, explore Blue Haven’s articles on presenting preliminary data and developing timelines and milestones.

Clarify the university relationship

Before proposal drafting, schedule a discussion with the appropriate university offices and company leadership. Use it to surface questions about:

·        Intellectual property ownership and the rights the company would need.

·        Access to university facilities, equipment, and personnel.

·        Research responsibilities and the proposed budget.

·        Investigator employment, effort, and availability.

·        University conflict-of-interest and outside-activity policies.

·        Agreements and approvals requiring institutional or legal review.

This is a recommended coordination checklist, not a statement that every project needs the same arrangement. The goal is a workable partnership—not a collaboration that exists only on the application’s organization chart.

Questions researchers ask

Can a university apply directly?

No. An eligible small business must be the SBIR/STTR applicant and award recipient. A university can participate through the appropriate research collaboration or subcontract.

Must a professor leave academia?

Not necessarily. NIH STTR allows the principal investigator’s primary employment to be with the partnering research institution or the small business, subject to its requirements. SBIR generally requires primary employment with the company at award and throughout the project. Confirm the proposed arrangement before choosing a program.

Is STTR automatically better for spinouts?

No. Evaluate the actual partnership, work allocation, investigator arrangements, and business eligibility. A university origin alone does not settle the choice.

Are SBIR phases clinical trial phases?

No. SBIR/STTR Phase I and Phase II describe stages of small-business funding; they are not the same as Phase I and Phase II clinical trials. The project’s clinical-trial status must also fit the selected funding opportunity.

Discuss your funding path

A useful consultation does not require a finished application. Start with a clear description of the product, the evidence available, the proposed company and university relationship, and the next development decision.

Blue Haven Grant Consultants helps medical-device and drug innovators evaluate funding fit and develop competitive NIH SBIR/STTR applications. With BHGC Pay Upon Award™, clients pay only if their proposal is awarded, under the terms of their engagement.

Developing a drug or medical device in an academic lab—or building a company around that research? Request a free funding consultation to discuss the project and the next step.